Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
AcelRx Pharmaceuticals, an opioid-drug maker, is buying Tetraphase Pharmaceuticals for a mere $14.4 million. Tetraphase sells Xerava, a tetracycline antibiotic administered via injection to treat multidrug-resistant infections. When Xerava was approved in August 2018, the firm’s stock rose to more than $70 a share; earlier this month it was trading for less than $1. Tetraphase has amassed losses of $600 million and sold only $3.6 million worth of Xerava in 2019.
This article has been sent to the following recipient: